Back to results
US 2015/0307882 A1Published application
Rnai-mediatred inhibition of frizzled related protein-1 for treatment of glaucoma
AssigneeArrowhead Research Corporation
InventorsAbbot F. Clark, Wan-Heng Wang, Loretta Graves McNatt
Life of this patent
Estimating the term…
Abstract
RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.
Claims21
A method of attenuating expression of Frizzled Related Protein-1 mRNA of a subject, comprising:
- administering to an eye of the subject a composition comprising an effective amount of interfering RNA and a pharmaceutically acceptable carrier, the interfering RNA comprising:
- a sense nucleotide strand, an antisense nucleotide strand, and a region of at least near-perfect contiguous complementarity of at least 19 nucleotides;
- wherein the antisense strand is 19 to 21 nucleotides and hybridizes to a nucleic acid sequence of any one of SEQ ID NO:
- 2, SEQ ID NO:
- 8-SEQ ID NO:
- 17, SEQ ID NO:
- 19-SEQ ID NO:
- 190, and SEQ ID NO:
- 192, wherein the thymines are replaced with uracils,
- wherein the expression of Frizzled Related Protein-1 mRNA is attenuated thereby.
7 more elements
A method of treating glaucoma in a subject in need thereof, comprising:
- administering to an eye of the subject a composition comprising an effective amount of interfering RNA, and a pharmaceutically acceptable carrier, the interfering RNA comprising a sense nucleotide strand, an antisense nucleotide strand, and a region of at least near-perfect contiguous complementarity of at least 19 nucleotides;
- wherein the antisense strand is 19 to 21 nucleotides and hybridizes to a nucleic acid sequence of any one of SEQ ID NO:
- 2, SEQ ID NO:
- 8-SEQ ID NO:
- 17, SEQ ID NO:
- 19-SEQ ID NO:
- 190, and SEQ ID NO:
- 192, wherein the thymines are replaced with uracils,
- wherein the glaucoma is treated thereby.
6 more elements
A composition comprising an interfering RNA having a length of 19 to 49 nucleotides, and comprising an nucleotide sequence corresponding to any one of SEQ ID NO:2, SEQ ID NO:8-SEQ ID NO:190, and SEQ ID NO:192, or a complement thereof;
- and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.